• FDA approves AZ's Lokelma for hyperkalaemia pharmafile
    May 25, 2018
    The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia.
PharmaSources Customer Service